MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Quanterix Corporation Operating Income 2011-2026 | QTRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Quanterix Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -126 M | -52.6 M | -46 M | -102 M | -58.6 M | -31.6 M | -41.6 M | -31.6 M | -26 M | -21.7 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.7 M | -126 M | -53.7 M |
Quarterly Operating Income Quanterix Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.3 M | -37.1 M | -26.4 M | - | -11.7 M | -10.9 M | -15.2 M | - | -9.56 M | -9.42 M | - | -36.6 M | -25 M | -18.2 M | - | -15.2 M | -13.7 M | -9.79 M | -9.93 M | 2.28 M | -12.2 M | -11.7 M | -11.5 M | -10.2 M | -10.5 M | -9.36 M | -9.41 M | -7.66 M | -7.31 M | -7.16 M | -7.09 M | -6.39 M | -6.47 M | -6.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.28 M | -37.3 M | -13.6 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 166.38 | -6.17 % | $ 12.5 B | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 33.72 | -4.58 % | $ 5.02 K | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 10.93 | -5.12 % | $ 1.64 B | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 9.07 | -3.41 % | $ 257 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.4 | 4.21 % | $ 41.1 M | USA |
 |
Abbott Laboratories
ABT
|
8.05 B | $ 103.99 | -0.55 % | $ 181 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.55 | 0.16 % | $ 208 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 69.17 | -1.43 % | $ 102 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Establishment Labs Holdings
ESTA
|
-39 M | $ 55.31 | -7.68 % | $ 1.64 B |  Costa-rica |
 |
CONMED Corporation
CNMD
|
103 M | $ 34.58 | -5.7 % | $ 1.07 B | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.59 | -1.18 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.15 | -5.29 % | $ 3.36 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 79.34 | -3.36 % | $ 46.4 B | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.92 | -4.48 % | $ 1.17 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 0.99 | -26.67 % | $ 16 M | USA |
 |
IRadimed Corporation
IRMD
|
26.1 M | $ 97.36 | -1.4 % | $ 1.24 B | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 85.33 | -1.73 % | $ 2.96 B | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 11.2 | -1.84 % | $ 1.51 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.52 | -5.08 % | $ 364 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-27 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.7 | 2.32 % | $ 29.3 M | USA |
 |
Penumbra
PEN
|
189 M | $ 335.1 | -0.39 % | $ 13 B | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 50.13 | -0.54 % | $ 1.47 B | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |